Description CJC-1295 No DAC 5mg Ipamorelin 5mg (10mg Blend) This formulation combines two well-characterized growth hormone–axis peptides into a single 10mg blended vial: CJC-1295 No DAC (5mg) and Ipamorelin (5mg). Both compounds are commonly studied for their interaction with endogenous growth hormone (GH) signaling pathways through distinct but complementary receptor mechanisms. This blend is intended strictly for laboratory and scientific research use. Mechanism of Action (Research Overview) CJC-1295 No DAC — GHRH Receptor Pathway CJC-1295 No DAC is a synthetic analog of growth hormone–releasing hormone (GHRH). It binds to GHRH receptors in the anterior pituitary, stimulating the release of endogenous growth hormone. The “No DAC” (Drug Affinity Complex) version is short-acting and does not bind to serum albumin, allowing researchers to evaluate more controlled and time-sensitive GH secretion patterns within experimental models. Ipamorelin — Ghrelin (GHS-R1a) Receptor Pathway Ipamorelin is a selective growth hormone secretagogue (GHS) that binds to the ghrelin receptor (GHS-R1a). Activation of this receptor stimulates endogenous GH release through a pathway distinct from GHRH receptor activation. Ipamorelin is frequently studied for its receptor selectivity and minimal activity at unrelated endocrine receptors in controlled laboratory settings. Dual-Receptor Activation Model When studied together, CJC-1295 No DAC and Ipamorelin allow researchers to examine: Simultaneous activation of GHRH and GHS receptor pathways Endogenous GH pulsatility patterns Downstream biomarker responses such as IGF-1 and IGFBP-3 Endocrine feedback loop dynamics This dual-pathway interaction is a primary reason the blend is frequently evaluated in GH-axis research models. Research Focus Areas This peptide blend has been explored in controlled research environments involving: Growth hormone secretion modeling IGF-1 and IGFBP-3 biomarker tracking Pulsatile hormone release analysis Metabolic signaling pathway investigation Endocrine receptor selectivity studies Combined GHRH GHS activation protocols These focus areas reflect endpoints measured in published scientific literature and are provided for informational context only. Key Research Characteristics Dual-peptide blend targeting distinct GH-axis receptors GHRH analog selective GHS receptor agonist Designed for endogenous GH secretion modeling Lyophilized (freeze-dried) for stability and long-term storage Product Specifications Compounds: CJC-1295 No DAC (5mg) Ipamorelin (5mg) Total Content: 10mg blended vial Form: Lyophilized powder Purity: High-purity, lab-tested Storage: Store refrigerated after reconstitution Why Fit Aminos Fit Aminos provides research-grade peptides manufactured under strict quality control standards to ensure purity, consistency, and reliability. Each batch is tested to support accurate and repeatable laboratory research outcomes. Important Notice This product is for research use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease.
